Bofanglutide
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
Gan & Lee Pharmaceuticals · Phase 2 · Completed · Enrollment 326
No selected arm has a reported week for this endpoint.
A solid line connects the weeks the source reports.